Smoothened Receptor Antagonists

Hedgehog Pathway Inhibitor

Skin Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Vismodegib is a hedgehog (Hh) pathway inhibitor, which is described chemically as 2-Chloro-<span class="Italics">N</span>-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide. The molecular formula is C<span class="Sub">19</span>H<span class="Sub">14</span>Cl<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">3</span>S. The molecular weight is 421.3 g/mol and the structural formula is:</p><div class="Figure"><img alt="Chemical Structure" src="erivedge-01.jpg"/></div><p>Vismodegib is a crystalline free base with a pKa (pyridinium cation) of 3.8, appearing as a white to tan powder. The solubility of vismodegib is pH dependent with 0.1 µg/mL at pH 7 and 0.99 mg/mL at pH 1. The partition coefficient (log P) is 2.7.</p><p>ERIVEDGE (vismodegib) for oral administration is supplied in capsules containing 150 mg vismodegib and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, sodium lauryl sulfate, povidone, sodium starch glycolate, talc, and magnesium stearate (non-bovine). The capsule shell contains gelatin, titanium dioxide, red iron oxide, and black iron oxide. The black printing ink contains shellac and black iron oxide.</p></section>

ERIVEDGE

vismodegib

vismodegib 150 MG Oral Capsule

Erivedge

vismodegib 150 MG Oral Capsule [Erivedge]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescription Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

How To Order Erivedge 

Billing & Coding Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Erivedge Prescriber Form & Patient Consent Form 

Erivedge Prescriber Service Form - Online Portal 

Patient Consent Form 

My Patient Solutions - HCP Portal (for managing service requests)

Enroll in Patient Savings Program 

Genentech Patient Foundation Application Form (1/2)

Genentech Patient Foundation Application Form (2/2) - Patient Consent Form 

Erivedge Prescriber Service Form ( For Dermatologists) 

Patient Case Studies 

About Erivedge 

Taking Erivedge 

Side Effects

Patient Support 

Patient Stories 

Instructions For Use: Basal Cell Carcinoma 

Patient Consent Form - Spanish